immuno-oncology

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

News

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

India’s Glenmark Pharma has added to its oncology pipeline by licensing rights to a checkpoint inhibitor from China’s Jiangsu Alphamab Biopharmaceuticals and 3D Medicines

News

CG Oncology is first biotech IPO of 2024, raising $380m

CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

CG Oncology lines up $180m IPO and a $1bn valuation

CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery i

FDA sets date for Adaptimmune’s sarcoma drug verdict

Keytruda improves survival in early-stage kidney cancer

Glenmark licenses cancer drug from China’s Alphamab, 3D Med

CG Oncology is first biotech IPO of 2024, raising $380m

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

CG Oncology lines up $180m IPO and a $1bn valuation

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

immuno-oncology

Editor's Picks